comparemela.com
Latest Breaking News On - Aboutocugen inc - Page 1 : comparemela.com
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity .
Los-angeles
California
United-states
Tarun-upadhyay
David-boyer
Lejla-vajzovic
Shankar-musunuri
Retina-vitreous-associates-medical-group
Ocugen-inc
Retina-foundation-of-the
Duke-university-school-of-medicine
Aboutocugen-inc
vimarsana © 2020. All Rights Reserved.